NMN

NMN sits between NR (nicotinamide riboside) and NAD+ in the salvage pathway. Whether it is superior to NR is the field's most public argument, largely a debate between David Sinclair's camp (NMN) and Charles Brenner's camp (NR). Both parties have commercial interests.

The scientific facts: NMN raises blood NAD+ in humans across multiple trials, at doses of 250-1000 mg/day. It is well-tolerated. Direct comparison studies against NR are rare and small. The claim that NMN is transported into cells intact via the Slc12a8 transporter is disputed. The competing claim, that NMN is dephosphorylated to NR before entering cells, is well-supported.

Human clinical benefits reported: modest improvements in aerobic capacity in older Japanese men, mild improvements in muscle function, some blood pressure reductions in metabolic syndrome. None of these are large effects.

Regulatory status matters. The US FDA excluded NMN from the supplement definition in 2022 because it had been investigated as a drug first, then lifted that exclusion on 29 September 2025. NMN is sold as a dietary supplement again in the US. Most other jurisdictions never restricted it. The FDA has not objected to the ingredient itself, but no NMN product carries an FDA approval, because supplements never do.

Quality varies. Third-party testing has repeatedly found NMN products significantly underdosed relative to their label claim. Look for products with a public Certificate of Analysis.

2026 Clinical Trial Update: First Large-Scale NMN RCT

The largest randomized, double-blind, placebo-controlled trial of NMN to date reported significant improvement in cognitive function [1]. Prior NMN human trials were small (n=20-80) and focused on physical endpoints like grip strength, walking speed, and insulin sensitivity. This trial extends the evidence base to cognitive outcomes, which are the endpoint most consumers care about.

A separate Nestle Health Science-led study found that 14-day supplementation of NR and NMN combined altered metabolic health markers in ways not previously described [2]. The study is industry-funded and not yet peer-reviewed, but it suggests NAD+ precursors may have metabolic effects beyond simple NAD+ elevation.

Early-phase trials of NAD+ precursors in Alzheimer's patients have also reported improvements in memory, physical movement, and metabolic health [3]. These are small, early-stage trials and should not be interpreted as evidence that NAD+ supplements treat or prevent Alzheimer's.

NMN Regulatory Context

NMN faces regulatory uncertainty in the US after FDA's 2022 determination that NMN cannot be marketed as a dietary supplement due to its prior investigation as a drug. The EU has not made a similar determination. Consumers should be aware that NMN availability may change based on regulatory decisions in different jurisdictions.

Products with this: NMN